1
|
Zuo C, Yan F, Wang J, Zhu Y, Luo W, Liu Y, Liang W, Yu W, Zhang J, Peng D, Ma X, Peng C. Design, synthesis, and evaluation of the novel ozagrel-paeonol codrug with antiplatelet aggregation activities as a potent anti-stroke therapeutic agent. Front Pharmacol 2024; 15:1362857. [PMID: 38567356 PMCID: PMC10985144 DOI: 10.3389/fphar.2024.1362857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2023] [Accepted: 03/05/2024] [Indexed: 04/04/2024] Open
Abstract
Introduction: Ischemic stroke is the second most common chronic disease worldwide and is associated with high morbidity and mortality. Thromboembolism and platelet aggregation are the most characteristic features of stroke. Other than aspirin, no standard, accepted, or effective treatment for acute ischemic stroke has been established. Consequently, it is essential to identify novel therapeutic compounds for this condition. Methods: In this study, novel ozagrel/paeonol-containing codrugs were synthesized and characterized using 1H-NMR, 13C-NMR, and mass spectroscopy. Their antiplatelet aggregation activity was evaluated, with compound PNC3 found to exhibit the best effect. Subsequently, studies were conducted to assess its neuroprotective effect, pharmacokinetic properties and model its binding mode to P2Y12 and TXA2, two proteins critical for platelet aggregation. Results: The results indicated that PNC3 has good bioavailability and exerts protective effects against oxygen-glucose deprivation injury in PC12 cells. Molecular docking analysis further demonstrated that the compound interacts with residues located in the active binding sites of the target proteins. Conclusion: The codrugs synthesized in this study display promising pharmacological activities and have the potential for development as an oral formulation.
Collapse
Affiliation(s)
- Chijing Zuo
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Fulong Yan
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Jie Wang
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Yulong Zhu
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Wenhui Luo
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Yan Liu
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Wanhui Liang
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Weidong Yu
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Jingwei Zhang
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Daiyin Peng
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
- MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials, Hefei, China
| | - Xiaodong Ma
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
| | - Can Peng
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China
- MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials, Hefei, China
- Generic Technology Research Center for Anhui TCM Industry, Anhui University of Chinese Medicine, Hefei, China
- Rural Revitalization Collaborative Technical Service Center of Anhui Province, Anhui University of Chinese Medicine, Hefei, China
- Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application, Hefei, Anhui, China
- Center for Xin’an Medicine and Modernization of Traditional Chinese Medicine of IHM, Anhui University of Chinese Medicine, Hefei, China
| |
Collapse
|
2
|
Haffouz A, Elleuch H, Khemakhem B, Ben Amor I, Jerbi A, Gargouri J, Sahli E, Mhadhbi N, Ghalla H, Rezgui F, Gargouri A, HadjKacem B. Antiplatelet activity and toxicity profile of novel phosphonium salts derived from Michael reaction. Eur J Pharm Sci 2024; 194:106692. [PMID: 38181870 DOI: 10.1016/j.ejps.2024.106692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 12/30/2023] [Accepted: 01/02/2024] [Indexed: 01/07/2024]
Abstract
In this work, five novel phosphonium salts derived from the Michael reaction were screened for their antiplatelet activity. Our findings revealed that compounds 2a, 2b, 2c, and 2d significantly inhibit platelet aggregation triggered by ADP or collagen (P < 0.001). Notably, compound 2c inhibited the arachidonic acid pathway (P < 0.001). Moreover, the selected compounds reduce CD62-P expression and inhibit GPIIb/IIIa activation. The interactions of the active compounds with their targets, ADP and collagen receptors, P2Y12 and GPVI respectively were investigated in silico using molecular docking studies. The results revealed a strong affinity of the active compounds for P2Y12 and GPVI. Additionally, cytotoxicity assays on platelets, erythrocytes, and human embryonic kidney HEK293 cells showed that compounds 2a, 2c and 2d were non-toxic even at high concentrations. In summary, our study shows that phosphonium salts can have strong antiplatelet power and suggests that compounds 2a, 2c and 2d could be promising antiplatelet agents for the management of cardiovascular diseases.
Collapse
Affiliation(s)
- Asma Haffouz
- Laboratory of Molecular Biotechnology of Eucaryotes, Centre of Biotechnology of Sfax, University of Sfax, B.P 1177, 3018, Sfax, Tunisia
| | - Haitham Elleuch
- Laboratory of Organic Chemistry, Faculty of Sciences, University Campus, 2092, University of Tunis El Manar, Tunis, Tunisia
| | - Bassem Khemakhem
- Laboratory of Plant Biotechnology, Sfax Faculty of Sciences, BP 1171, University of Sfax, 3038 Sfax, Tunisia
| | - Ikram Ben Amor
- Laboratory of Hematology (LR19SP04), Medical Faculty of Sfax. University of Sfax, Magida Boulila Avenue, 3029 Sfax, Tunisia
| | - Amira Jerbi
- Laboratory of Hematology (LR19SP04), Medical Faculty of Sfax. University of Sfax, Magida Boulila Avenue, 3029 Sfax, Tunisia
| | - Jalel Gargouri
- Laboratory of Hematology (LR19SP04), Medical Faculty of Sfax. University of Sfax, Magida Boulila Avenue, 3029 Sfax, Tunisia
| | - Emna Sahli
- Analytical service provider unit, Centre of Biotechnology of Sfax, University of Sfax, 3018, Sfax, Tunisia
| | - Noureddine Mhadhbi
- Laboratory Physico Chemistry of the Solid State, Department of Chemistry, Faculty of Sciences, University of Sfax, BP 1171, 3000 Sfax, Tunisia; University of Monastir, Preparatory Institute for Engineering Studies of Monastir, 5019 Monastir, Tunisia
| | - Houcine Ghalla
- Quantum Physics and Statistic Laboratory, Faculty of Sciences, University of Monastir, Monastir, 5000, Tunisia
| | - Farhat Rezgui
- Laboratory of Organic Chemistry, Faculty of Sciences, University Campus, 2092, University of Tunis El Manar, Tunis, Tunisia
| | - Ali Gargouri
- Laboratory of Molecular Biotechnology of Eucaryotes, Centre of Biotechnology of Sfax, University of Sfax, B.P 1177, 3018, Sfax, Tunisia
| | - Basma HadjKacem
- Laboratory of Molecular Biotechnology of Eucaryotes, Centre of Biotechnology of Sfax, University of Sfax, B.P 1177, 3018, Sfax, Tunisia; Department of Life Sciences, Faculty of Sciences of Gafsa, University of Gafsa, Gafsa, Tunisia.
| |
Collapse
|